Literature DB >> 3315000

Mutants of polyomavirus middle-T antigen.

W Markland1, A E Smith.   

Abstract

Polyomavirus middle-T antigen induces the transformation of established cell lines in culture and is known to interact with and/or modulate the activity of several enzymes (pp60c.src, protein kinase C and phosphatidylinositol kinase) in vitro. This review is a compilation of the reported mutants of middle-T antigen and their biochemical and biological properties as they relate to the transformation event. The mutants of polyomavirus middle-T antigen have been previously classified phenotypically. Given the now large number of mutants, the classification presented here is based upon the position within the molecule. A model of middle-T is presented in which the protein is considered as consisting of three domains: a hydrophobic domain (the putative membrane-binding domain), the amino-terminal half of the molecule (the putative pp60c.src-binding domain) and the intervening amino acids (the putative modulatory domain). A current model for the induction of transformation by polyomavirus middle-T is presented.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315000     DOI: 10.1016/0304-419x(87)90011-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  21 in total

Review 1.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

2.  Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control.

Authors:  Pablo Rodriguez-Viciana; Crista Collins; Mike Fried
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-08       Impact factor: 11.205

3.  Mitosis-specific phosphorylation of polyomavirus middle-sized tumor antigen and its role during cell transformation.

Authors:  L Pérez; A Paasinen; B Schnierle; S Käch; M Senften; K Ballmer-Hofer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

4.  A completely transformation-defective point mutant of polyomavirus middle T antigen which retains full associated phosphatidylinositol kinase activity.

Authors:  B J Druker; L E Ling; B Cohen; T M Roberts; B S Schaffhausen
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

5.  pp60c-src binding to polyomavirus middle T-antigen (MT) requires residues 185 to 210 of the MT sequence.

Authors:  C E Brewster; H R Glover; S M Dilworth
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Cellular proteins that associate with the middle and small T antigens of polyomavirus.

Authors:  D C Pallas; V Cherington; W Morgan; J DeAnda; D Kaplan; B Schaffhausen; T M Roberts
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

7.  Recombinant retroviruses that transduce middle T antigen cDNAs derived from polyomavirus mutants: separation of focus formation and soft-agar growth in transformation assays and correlations with kinase activities in vitro.

Authors:  W C Morgan; D R Kaplan; D C Pallas; T M Roberts
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

8.  Genetic evidence that acute morphologic transformation, induction of cellular DNA synthesis, and focus formation are mediated by a single activity of the bovine papillomavirus E5 protein.

Authors:  J Settleman; A Fazeli; J Malicki; B H Horwitz; D DiMaio
Journal:  Mol Cell Biol       Date:  1989-12       Impact factor: 4.272

9.  Mutation of a cysteine residue in polyomavirus middle T antigen abolishes interactions with protein phosphatase 2A, pp60c-src, and phosphatidylinositol-3 kinase, activation of c-fos expression, and cellular transformation.

Authors:  G M Glenn; W Eckhart
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Novel monoclonal antibodies that differentiate between the binding of pp60c-src or protein phosphatase 2A by polyomavirus middle T antigen.

Authors:  S M Dilworth; V P Horner
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.